Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Diabetes Care

Volumn 27, Issue 11, 2004, Pages 2628-2635

  Buse, John B ^a   Henry, Robert R ^b   Han, Jenny ^c   Kim, Dennis D ^c   Fineman, Mark S ^c   Baron, Alain D ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE; HEMOGLOBIN A1C; PLACEBO; PROINSULIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; PROINSULIN; RETREATMENT; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE; VENOMS; WEIGHT LOSS;

EID: 7444228521     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.11.2628     Document Type: Article

References (38)

1. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999
2. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 137:25-33, 2002
3. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
4. UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
5. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
6. UK Prospective Diabetes Study Group: U.K. Prospective Diabetes Study 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 21:87-92, 1998
7. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089, 2003
8. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377, 2003
9. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opinion Invest Drugs 4:401-405, 2003
10. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034, 1999
11. Parkes DG, Pittner R, Jodka C, Smith P, Young A: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 50:583-589, 2001
12. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161, 2001
13. World Medical Association Declaration of Helsinski: recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 277:925-926, 1997
14. Fineman MS, Shen LZ, Kristin Taylor T, Kim DD, Baron AD: Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side-effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. In press
15. Groop LC: Sulfonylureas in MDDM. Diabetes Care 15:737-754, 1992
16. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wahlin-Boll E, Melander A, DeFronzo RA: Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 14:724-727, 1991
17. Wahlin-Boll E, Sartore G, Melander A, Schersten B: Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 22:21-25, 1982
18. Neter J, Wasserman W, Kutner MH: Applied linear Statistical Models: Regression, Analysis of Variance, and Experimental Designs. 3rd ed. Homewood, IL, Irwin, 1990
19. Milliken GA, Johnson DE: Analyses of Messy Data: Vol I: Designed Experiments. New York, Van Nostrand Reinhold, 1984
20. Hayter AJ: The maximum familywise error rate of Fisher's least significant difference test. J Am Statistical Assoc 396:1000-1004, 1986
21. Davis JE, McDonald JM, Jarret L: A high-performance liquid chromatography method for hemoglobin A1c. Diabetes 27:102-107, 1978
22. Cole RA, Soeldner JS, Dunn PJ, Bunn HF: A rapid method for the determination of glycosylated hemoglobins using high pressure liquid chromatography. Metabolism 27:289-301, 1978
23. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
24. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408, 1999
25. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372, 2002
26. Egan JM, Clocquet AR, Elahi D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290, 2002
27. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655, 1993
28. Nielsen LL, Young AA, Parkes D: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Reg Pept 117:77-88, 2004
29. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinol 141:1936-1941, 2000
30. Willms B, Ruge D: Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomized, placebo-controlled study. Diabet Med 16:755-761, 1999
31. Blonde L, Rosenstock J, Mooradian AD, Pipe BA, Henry D: Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 4:368-375, 2002
32. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
33. Gregorio F, Ambrosi F, Marchetti P Cristallini S, Navalesi R, Brunetti P, Filipponi P: Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations. Acta Diabetol Lat 27:139-155, 1990
34. Higginbotham L, Matin FI: Double-blind trial of metformin in the therapy of non-ketotic diabetics. Med J Aust 2:154-156, 1979
35. Cusi K, Consoli A, DeFronzo RA: Metabolic effects of metformin on glucose and lactate metabolism in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067, 1996
36. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147, 2004
37. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 285:E155-E162, 2003
38. DeFronzo R, Ratner R, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes (Abstract). American Diabetes Association 64th Annual Scientific Sessions, 2004 (6-LB late-breaking abstract).